Loading...
OTCM
ACUR
Market cap6kUSD
Jul 09, Last price  
0.00USD
1D
9,900.00%
1Q
-50.00%
Jan 2017
-99.99%
IPO
-100.00%
Name

Acura Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:ACUR chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-12.12%
Revenues
0k
-100.00%
5,750,000838,0008,205,00006,404,00044,437,0003,835,0003,311,00020,466,00020,466,000123,000751,0008,587,0004,464,0002,966,000410,0002,657,0003,570,0001,563,0000
Net income
0k
P
-48,455,000-69,996,000-12,075,000-5,967,000-4,314,00014,474,000-15,835,000-12,707,00010,385,000-9,668,000-13,901,000-13,209,000-4,989,000-7,388,000-5,682,000-3,842,000-3,774,000-1,208,000-879,0000
CFO
0k
P
-16,085,000-9,493,000-5,527,000-5,383,00019,220,0004,191,000-5,203,000-6,480,00012,312,000-7,038,000-13,678,000-11,044,000-3,688,000-5,563,000-4,510,000-3,908,000-618,000-719,000-742,0000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain. The company also offers the Nexafed line, consisting of pseudoephedrine and acetaminophen tablets, widely utilized as nasal decongestants in a range of over-the-counter and prescription formulations for cold, sinus, and allergy relief. Beyond its current offerings, Acura is actively advancing six additional opioid products through various stages of formulation development. To support its global reach, Acura Pharmaceuticals maintains strategic collaboration and licensing agreements with Egalet US, Inc. and Egalet Ltd. for the worldwide production and commercialization of its Oxaydo products. Furthermore, it has established a development and commercialization partnership with Abuse Deterrent Pharma, LLC to create LTX-03, an immediate-release tablet leveraging the proprietary LIMITx technology. Established in 1935, the company's operations are headquartered in Palatine, Illinois.
URL
http://acurapharm.com/
IPO date
Sep 12, 2000
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT